by Nicole Kuchinsky | Nov 8, 2016
A key driver for advancements in regenerative medicine is partnerships. In recognition of this, every year CCRM hosts a networking reception that brings together our partners for an evening of discussion and knowledge sharing. This year’s industry networking reception...
by Michael May | Aug 30, 2016
Michael May is President and CEO of CCRM, a leader in developing and commercializing regenerative medicine, cell and gene therapy technologies, Michael Rudnicki is Scientific Director and CEO of Stem Cell Network, with a mandate to translate stem cell research into...
by Mark Curtis | Jun 30, 2016
Welcome to your update from the clinic for the month of May. Long-standing industry pioneer StemCells, Inc. decided to wind down its operations after a failed Phase 2 study in spinal cord injury. Aduro Biotech also saw a failure with its GVAX product in pancreatic...
by James Smith | Jun 28, 2016
This post was authored by Kelvin Ng and James Smith. Completing his PhD this year in the Karp lab at MIT/Harvard, Kelvin focuses on strategies and technologies that guide or accelerate the translation of therapeutic extracellular vesicles. His multidisciplinary...
by Mark Curtis | Jun 23, 2016
Welcome to your deal review for the month of May. Intellia Therapeutics went public this past month giving investors a second shot on net if they want to gain exposure to gene editing technologies. Caladrius Biosciences spun-out its cell-based immunotherapy to AiVita...
Comments